Plasma Clusterin and the Risk of Alzheimer Disease

被引:168
|
作者
Schrijvers, Elisabeth M. C. [1 ,2 ]
Koudstaal, Peter J. [2 ]
Hofman, Albert [1 ]
Breteler, Monique M. B. [1 ,3 ]
机构
[1] Univ Med Ctr, Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands
[2] Univ Med Ctr, Erasmus MC, Dept Neurol, NL-3000 CA Rotterdam, Netherlands
[3] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany
来源
关键词
GENOME-WIDE ASSOCIATION; IDENTIFIES VARIANTS; APOLIPOPROTEIN-J; MENTAL STATE; DIAGNOSIS; DEMENTIA; CLU;
D O I
10.1001/jama.2011.381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Variants in the clusterin gene are associated with the risk of Alzheimer disease (AD) and clusterin levels have been found to be increased in brain and cerebrospinal fluid of patients with AD. Plasma clusterin was reported to be associated with brain atrophy, baseline disease severity, and rapid clinical progression in patients with AD. Objective To evaluate the potential of plasma clusterin as a biomarker of the presence, severity, and risk of AD. Design, Setting, and Participants A case-cohort study nested within the Rotterdam Study, a prospective population-based cohort study conducted in Rotterdam, the Netherlands. Plasma levels of clusterin were measured at baseline (1997-1999) in 60 individuals with prevalent AD, a random subcohort of 926 participants, and an additional 156 participants diagnosed with AD during follow-up until January 1, 2007 (mean [SD], 7.2 [2.3] years). Main Outcome Measures Prevalent AD, severity of AD measured by the Mini-Mental State Examination (MMSE) score, and the risk of developing AD during follow-up. Results The likelihood of prevalent AD increased with increasing plasma levels of clusterin (odds ratio [OR] per SD increase of plasma clusterin level, 1.63; 95% confidence interval [CI], 1.21-2.20; adjusted for age, sex, education level, apolipoprotein E status, diabetes, smoking, coronary heart disease, and hypertension). Among patients with AD, higher clusterin levels were associated with more severe disease (adjusted difference in MMSE score per SD increase in clusterin levels, -1.36; 95% CI, -2.70 to -0.02; P=.047). Plasma clusterin levels were not related to the risk of incident AD during total follow-up (adjusted HR, 1.00; 95% CI, 0.85-1.17; P for trend=.77) or within 3 years of baseline (adjusted HR, 1.09; 95% CI, 0.84-1.42; P for trend=.65). Conclusion Plasma clusterin levels were significantly associated with baseline prevalence and severity of AD, but not with incidence of AD. JAMA. 2011;305(13):1322-1326 www.jama.com
引用
收藏
页码:1322 / 1326
页数:5
相关论文
共 50 条
  • [21] Blood Clusterin Levels, rs9331888 Polymorphism, and the Risk of Alzheimer's Disease
    Xing, Yao-Yao
    Yu, Jin-Tai
    Cui, Wei-Zhen
    Zhong, Xiao-Ling
    Wu, Zhong-Chen
    Zhang, Qun
    Tan, Lan
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2012, 29 (03) : 515 - 519
  • [22] The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer's disease
    Hsu, Jung-Lung
    Lee, Wei-Ju
    Liao, Yi-Chu
    Wang, Shuu-Jiun
    Fuh, Jong-Ling
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2017, 9
  • [23] Plasma homocysteine levels and risk of Alzheimer disease
    Luchsinger, JA
    Tang, MX
    Shea, S
    Miller, J
    Green, R
    Mayeux, R
    [J]. NEUROLOGY, 2004, 62 (11) : 1972 - 1976
  • [24] Clusterin transduces Alzheimer-risk signals to amyloidogenesis
    Xi Liu
    Rongbo Che
    Wenping Liang
    Yun Zhang
    Liyong Wu
    Chao Han
    Hong Lu
    Weihong Song
    Yili Wu
    Zhe Wang
    [J]. Signal Transduction and Targeted Therapy, 7
  • [25] The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer’s disease
    Jung-Lung Hsu
    Wei-Ju Lee
    Yi-Chu Liao
    Shuu-Jiun Wang
    Jong-Ling Fuh
    [J]. Alzheimer's Research & Therapy, 9
  • [26] Clusterin transduces Alzheimer-risk signals to amyloidogenesis
    Liu, Xi
    Che, Rongbo
    Liang, Wenping
    Zhang, Yun
    Wu, Liyong
    Han, Chao
    Lu, Hong
    Song, Weihong
    Wu, Yili
    Wang, Zhe
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
  • [27] Clusterin is a Potential Therapeutic Target in Alzheimer's Disease
    Palihati, Nazhakaiti
    Tang, Yuanhong
    Yin, Yajuan
    Yu, Ding
    Liu, Gang
    Quan, Zhenzhen
    Ni, Junjun
    Yan, Yan
    Qing, Hong
    [J]. MOLECULAR NEUROBIOLOGY, 2023, 61 (7) : 3836 - 3850
  • [28] Relationship between multifunctional protein ''clusterin'' and Alzheimer disease
    ChoiMiura, NH
    Oda, T
    [J]. NEUROBIOLOGY OF AGING, 1996, 17 (05) : 717 - 722
  • [29] Plasma Clusterin as a Potential Biomarker for Alzheimer's Disease-A Systematic Review and Meta-analysis
    Shi, Xin Rui
    Xie, Bei Jia
    Xing, Yi
    Tang, Yi
    [J]. CURRENT ALZHEIMER RESEARCH, 2019, 16 (11) : 1018 - 1027
  • [30] Role of Plasma Clusterin in Alzheimer's Disease-A Pilot Study in a Tertiary Hospital in Northern India
    Vishnu, Venugopalan Y.
    Modi, Manish
    Sharma, Sandeep
    Mohanty, Manju
    Goyal, Manoj Kumar
    Lal, Vivek
    Khandelwal, Niranjan
    Mittal, Bhagwant Rai
    Prabhakar, Sudesh
    [J]. PLOS ONE, 2016, 11 (11):